Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Neuphoria Therapeutics Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- −1 vs. Q4 2024
- Shares held
- 163.1K
- +83.4K (+104.6%) vs. Q4 2024
- Total value
- $935.4K
- +$661.9K (+242.1%) vs. Q4 2024
- New holders
- 3
- 0 more added
- Sold out
- 4
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEUP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $8.71M |
| Q1 2026 | 19 | $7.15M |
| Q4 2025 | 21 | $5.69M |
| Q3 2025 | 15 | $2.30M |
| Q2 2025 | 9 | $1.26M |
| Q1 2025 | 7 | $935.4K |
| Q4 2024 | 8 | $273.4K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Neuphoria Therapeutics Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 69,659 | $397.1K | 0.08% | +69,659 | New |
| Lynx1 Capital Management LP | 45,806 | $263.8K | 0.09% | 00.0% | Unchanged |
| Prosperity Wealth Management, Inc. | 27,200 | $156.7K | 0.07% | +27,200 | New |
| Merck & Co., Inc. | 10,027 | $57.8K | 0.04% | 00.0% | Unchanged |
| Cyndeo Wealth Partners, LLC | 10,000 | $57.6K | 0.00% | +10,000 | New |
| Rhumbline Advisers | 415 | $2.39K | 0.00% | −691−62.5% | Reduced |
| Morgan Stanley | 7 | $40 | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −13,311−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −6,484−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,978−100.0% | Sold out |
| Hanson & Doremus Investment Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |